Regulus Therapeutics Inc To Host Investor Event (Virtual) Transcript
Hello, and thank you for joining us today for this Investor Event regarding our ADPKD program. We will be making forward-looking statements today. Actual results may differ materially from those discussed, and we encourage you to review our SEC filings, including our most recent 10-Q regarding risk factors related to our business.
Our objectives today are to provide a background on Regulus and our ADPKD program. We also have assembled a number of leaders in the field of ADPKD to discuss the disease, its genetic drivers, the role of miR-17 and new ways to characterize the disease's evolution. We also will be presenting our Next-gen (inaudible) oligo, RGLS8429's role to discovery and preclinical validation data. And then our colleagues at Regulus will discuss our clinical development plans going forward and longer-term strategy, after which we'll have time for questions and answers.
A bit of a brief background on Regulus. Regulus was established in 2007 as a joint venture between two leaders in all of the nucleotides, [Ionis]
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
